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The  disease  entity  today  widely  called  ‘primary  biliary
irrhosis’  was  ﬁrst  described  by  Addison  &  Gull  in  1851  [1]
nd  Hanot  in  1876  [2].  One  hundred  years  after  its  ﬁrst
escription,  MacMahon  &  Thannhauser  proposed  the  term
xanthomatous  biliary  cirrhosis’  for  this  disease  based  on  the
ypical  xanthoma  formation  with  accumulation  of  choles-
erol  esters  in  the  skin  around  the  eyes  in  association  with
nﬂammatory  destruction  of  small  intrahepatic  bile  ductules
eading  to  a  biliary  type  cirrhosis  [3].  Xanthoma  formation,
owever,  is  not  a  very  common  sign  in  this  disorder.  This
ay  be  the  reason  why  the  term  ‘primary  biliary  cirrhosis’,
roposed  one  year  later  for  the  same  disorder  by  Ahrens
t  al.,  [4]  gained  wider  acceptance  when  most  patients  were
resenting  with  advanced  liver  disease.
Dame  Sheila  Sherlock,  already  in  1959,  opposed  the  term
primary  biliary  cirrhosis’  as  many  of  her  patients  were
ree  of  cirrhosis  at  the  time  of  diagnosis  and  the  mean
urvival  was  5  and  a  half  years  (3—11)  even  for  the  fatal
ases,  whereas  many  asymptomatic  patients  would  survive
ore  than  10  years  [5].  The  term  ‘primary  biliary  cir-
hosis’  remained  an  issue  of  concern  as  reﬂected  by  the
ame  change  proposal  of  Rubin,  Schaffner  and  Popper  in
965  with  their  paper  ‘Primary  biliary  cirrhosis—Chronic
on-suppurative  destructive  cholangitis’  [6].  S.  Sherlock
isely  commented  on  this  new  name:  ‘‘.  .  .a better  one,
lthough  it  is  unlikely  that  it  will  replace  the  more  popu-
ar,  although  inaccurate,  one  of  primary  biliary  cirrhosis’’
7].  She  was  right,  again.  And  even  40  years  later,  the  Euro-
ean  [8]  and  American  [9]  Clinical  Practice  Guidelines  still
sed  the  term  ‘primary  biliary  cirrhosis’  even  though  it  was
n  anachronism  and  did  not  accurately  reﬂect  the  natural
istory  of  disease  in  the  vast  majority  of  patients  as  it  is
oday.
The  early  diagnosis  of  primary  biliary  cirrhosis  has  dra-
atically  improved  with  the  more  accurate  measurements
f  markers  of  cholestasis  and  improvements  in  the  detec-
ion  of  the  classic  serologic  hallmark,  anti-mitochondrial
ntibodies.  Furthermore,  the  prognosis  has  dramatically
mproved  with  the  introduction  of  orthotopic  liver  trans-
lantation  in  the  1970s  and  1980s,  and  of  ursodeoxycholic
cid  (UDCA,  13—15  mg/kg  daily)  treatment  in  the  1980s  and
990s.  Today,  two  out  of  three  patients  diagnosed  with
rimary  biliary  cirrhosis  and  treated  with  UDCA  have  an
xpected  survival  not  different  from  the  general  population
nd  only  a  minority  will  ever  develop  cirrhosis.
The  pathogenesis  of  primary  biliary  cirrhosis  remains
nigmatic  although  enormous  progress  has  been  made  in
nravelling  genetic,  immunological  and  pathophysiological
olecular  mechanisms  involved  [10—13].  This  has  also  led  to
ew  therapeutic  approaches  which  are  now  under  evaluation
14,15].
On 23—24  May,  2014,  the  2nd  European  Association  for
he  Study  of  the  Liver  (EASL)  Monothematic  Conference
n  Primary  Biliary  Cirrhosis  took  place  in  Milan,  Italy.  On
his  occasion,  patient  representatives  from  the  UK  and
ermany,  Robert  Mitchell-Thain  and  Ingo  van  Thiel,  rep-
esenting  numerous  national  patient  groups  from  different
arts  of  the  world  requested  to  change  the  name  of  ‘primary
iliary  cirrhosis’  to  ‘‘correct  the  inaccuracy’’  and  ‘‘remove
he  cirrhosis  stigma’’  as  well  as  all  the  misunderstanding,
isadvantages  and  discriminations  emanating  from  this  mis-
omer  in  daily  life  of  the  patients.
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This  initiative  was  based  on  former  discussions  at  a
eeting  with  international  patient  advocates  and  medical
xperts  led  by  Raoul  Poupon  of  France  during  the  EASL
nternational  Liver  Congress  2014  in  London,  and  based
n  part  on  worldwide  survey  by  patient  support  groups
erformed  among  >  1200  patients  with  primary  biliary
irrhosis.
E-mail  discussions  among  experts  in  the  ﬁeld  before
he  meeting,  as  well  as  intense  discussions  during  the
ASL  Monothematic  Conference  in  Milan  with  contin-
al  e-mail  exchanges  after  the  meeting  has  led  to  the
idespread  view  among  the  vast  majority  of  worldwide
xperts  that;  (1)  the  name  ‘primary  biliary  cirrhosis’  should
e  changed  [as  advocated  by  Dame  Sheila  Sherlock  in
959].  In  addition,  the  following  proposals  found  broad
upport  among  the  discussants;  (2)  the  acronym  ‘PBC’
hould  be  kept  if  possible;  (3)  a  simple  and  short  term
hould  be  used  (imperfection  acceptable)  as  long  as  the
xact  pathogenesis  of  primary  biliary  cirrhosis  remained
ndeﬁned  and,  therefore,  an  ‘ideal’  replacement  is  not
vailable.
In  parallel  with  the  growing  patient  support  from  Europe
nd  the  U.S.,  several  surveys  were  performed  among
nternational  experts  in  the  ﬁeld.  Among  EASL-selected
ommittee  members  and  senior  reviewers  of  the  EASL
uidelines  for  management  of  cholestatic  liver  diseases
n  =  15),  100%  agreed  to  a  name  change  for  primary  bil-
ary  cirrhosis  and  100%  voted  to  keep  the  abbreviation
PBC’.  60%  preferred  ‘primary  biliary  cholangitis’,  20%  ‘pri-
ary  biliary  cholangiopathy’,  and  20%  various  other  names.
mong  international  experts  from  the  American  Associa-
ion  for  the  Study  of  Liver  Disease  (AASLD),  Asian  Paciﬁc
ssociation  for  the  Study  of  the  Liver  (APASL)  and  EASL
outside  the  EASL  committees]  (n  =  16),  88%  agreed  to  a
ame  change  for  primary  biliary  cirrhosis  and  88%  voted
o  keep  the  abbreviation  ‘PBC’.  56%  preferred  ‘primary
iliary  cholangitis’,  13%  ‘primary  biliary  cholangiopathy’,
nd  38%  various  other  names.  Among  Japanese  experts
n  =  18),  100%  agreed  to  a  name  change  for  primary  bil-
ary  cirrhosis  and  78%  voted  to  keep  the  abbreviation
BC.  61%  preferred  ‘primary  biliary  cholangitis’,  28%  ‘pri-
ary  biliary  cholangiopathy’,  and  11%  various  other  names.
hus,  considering  that  imperfection  was  acceptable  in  name
nding,  ‘primary  biliary  cholangitis’  found  the  broadest
upport  as  the  new  name  for  PBC  among  experts  world-
ide.
Our  goal,  as  physicians,  is  to  help  and  heal  our  patients
oth  actively  at  the  bedside  but  also  passively  in  everyday
ocial  challenges  as  patients  balance  their  personal  lives
ith  their  clinical  needs.  Our  misuse  of  the  name  ‘cirrhosis’
s  counterproductive  to  our  support  and  our  role  as  physi-
ians.  We  should  also  note  that  the  change  of  name  for  an
utoimmune  disease  is  not  without  precedence:  Wegener’s
ranulomatosis  for  example  is  now  known  as  granulomatous
olyangiitis.
The  proposal  for  a  name  change  of  primary  biliary  cirrho-
is  to  ‘primary  biliary  cholangitis’  was  approved  by  the  EASL
overning  Board  in  November  2014,  by  the  AASLD  Governing
oard  in  April  2015  and  by  the  American  Gastroenterological
ssociation  (AGA)  Governing  Board  in  July  2015.  A  vote  of  the
PASL  Governing  Board  and  the  United  European  Gastroen-
erology  (UEG)  Governing  Board  was  pending  at  the  moment
gitis’
R
[
[
[
[
[
[
[
[
[
[
[Changing  nomenclature  for  PBC:  From  ‘cirrhosis’  to  ‘cholan
this  article  was  written,  whereas  support  by  respected  Gov-
erning  Board  members  from  both  associations  was  provided
beforehand.
What  are  the  next  steps?  The  World  Health  Organization
(WHO)  is  asking  medical  professionals  for  the  ﬁrst  time  to
help  in  the  revision  process  of  the  diagnosis  and  symptom
codes  (International  Classiﬁcation  of  Diseases  11th  Revision,
ICD-11).
The  medical  representatives  of  the  ‘‘Name  Change  Ini-
tiative  for  PBC’’—with  support  of  the  international  primary
biliary  cirrhosis  patient  groups—will  take  responsibility  to
submit  the  joint  proposal  of  international  experts  around
the  world  for  the  name  ‘primary  biliary  cholangitis’.
We  are  aware  of  the  imperfection  of  the  new  simple  name
and  agree  that  alternative  proposals  like  primary  small  bile
duct  cholangitis,  primary  intrahepatic  cholangitis,  primary
small  bile  duct  cholangiopathy,  primary  biliary/peripheral
(destructive)  cholangitis,  or  primary  cholangiohepatitis  may
come  somewhat  closer  to  what  we  think  this  inﬂammatory
liver  disorder  is  about.  However,  we  would  kindly  remind
all  critics  of  the  fate  of  Hans  Popper’s  carefully  chosen
‘chronic  non-suppurative  destructive  cholangitis’—too  dif-
ﬁcult  according  to  the  late  Dame  Sheila  Sherlock.  It  failed
to  reach  sufﬁcient  support.
‘Primary  biliary  cholangitis’  is  a  tautology  (‘‘saying  the
same  thing  twice’’),  some  critics  say.  But  is  that  true?
‘Cholangitis’  adequately  describes  the  dense  inﬂammatory
inﬁltrates  around  small  damaged  interlobular  bile  ductules.
Recent  experimental  evidence  suggests  that  hydrophobic
bile  acids  in  bile,  the  major  biliary  organic  solutes,  may
play  a  crucial  role  in  the  initiation  of  inﬂammation  in  pri-
mary  biliary  cirrhosis  [16—21].  Future  research  will  teach  us
whether  we  have  chosen  a  simple  and,  beyond  that,  reason-
able  name.
The  new  term  ‘primary  biliary  cholangitis’  will  lead
to  confusion  in  daily  clinical  practice  with  other  forms
of  immunemediated  cholangitis  such  as  primary  sclerosing
cholangitis  (PSC),  some  critics  say.  Indeed,  the  term  ‘cholan-
gitis’  is  a  general  description  of  an  inﬂammatory  disorder
of  the  intra-  and/or  extrahepatic  bile  ducts  as  is  ‘cirrhosis’
for  the  description  of  replacement  of  normal  liver  tissue  by
scar  tissue.  The  name  change  for  primary  biliary  cirrhosis
offers  the  unique  opportunity  for  new  awareness  campaigns
among  medical  professionals  as  well  as  patient  groups  to
draw  more  attention  to  immunemediated  biliary  diseases
like  PBC  or  PSC  and,  ultimately,  their  early  correct  diagnosis
and  treatment.
From  ‘cirrhosis’  to  ‘cholangitis’—the  change  has  criti-
cal  implications  for  patients.  It  removes  the  stigmata  of
cirrhosis  and  its  implications  of  alcohol  abuse.  It  removes
the  stigmata  of  a  poor  prognosis.  Its  removal  reminds
patients  that  they  are  living  with  this  syndrome,  not  dying
of  it.  Its  removal  improves  their  opportunities  in  the
workplace  and  in  their  everyday  social  lives.  Thus,  we  sin-
cerely  call  on  all  medical  professionals  and  all  patients
and  their  families  and  friends  worldwide  to  use  from  this
moment  on  the  name  ‘‘primary  biliary  cholangitis’’  for
the  disease  known  by  its  abbreviation  PBC!  We  owe  this
to  our  patients  and  to  further  our  role  as  caring  physi-
cians.
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